Benefits of combination therapy in hypertensive patients with associated Coronary Artery Disease: A subgroup with specific demands

Journal of Cardiovascular Pharmacology

Volumn 31, Issue SUPPL. 2, 1998, Pages

  Morisco, C ^b   Lembo, G ^b   Sarno, D ^a   Argenziano, L ^a   Fratta, L ^a   Rozza, F ^a   Trimarco, B ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

ACE inhibitors; Calcium antagonists; Endothelial function; Essential hypertension; Left ventricular hypertrophy; Myocardial infarction

Indexed keywords

CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG COMBINATION; DRUG EFFECT; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HUMAN; HYPERTENSION; METABOLISM; OXYGEN CONSUMPTION; REVIEW;

CLINICAL TRIALS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; OXYGEN CONSUMPTION;

EID: 0031630073     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199800002-00005     Document Type: Article

References (48)

1. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, part I: effects of prolonged differences in blood pressure. Evidence from nine prospective observational studies corrected for the regression dilution bias. Lancet 1990;335: 765-74.
2. Standgaard S, Haunso S. Why does antihypertensive treatment prevent stroke but not myocardial infarction? Lancet 1987;2:658-60.
3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease, part II: effects of short-term reductions in blood pressure. An overview of the unconfounded randomized drug trials in their epidemiological context. Lancet 1990;335:827-38.
4. Waeber B, Brunner HR. Main objectives and new aspects of combination treatment of hypertension. J Hypertens 1995;13(suppl 2): S15-9.
5. Brouwer RH, Balli P, Erue P, et al. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol 1985;7(suppl 1):S88-91.
6. Singer DR, Markandu ND, Shore AC, MacGregor GA. Captopril and nifedipine in combination for moderate to severe essential hypertension. Hypertension 1987;9:629-33.
7. Singer DR, Markandu ND, Cappuccio FP, MacGregor GA. Studies of captopril alone and in combination with the benzothiazepine diltiazem or the dihydropyridine nifedipine in treating essential hypertension. J Cardiovasc Pharmacol 1991;18(suppl 9):S51-4.
8. Cappuccio FP, Markandu MD, Singer DRJ, MacGregor GA. Amlodipine and lisinopril in combination for the treatment of essential hypertension: efficacy and predictors of response. J Hypertens 1993;11:839-47.
9. Gilman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham study. Am Heart J 1993;125:1148-54.
10. Kannel WB, Dauenberg AL, Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol 1987;60:851-931.
11. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
12. Burke AP, Farb A, Liang Y, et al. Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death. Circulation 1996;94:3138-45.
13. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
14. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991;83:1771-9.
15. Hess OA, Villari B, Krayenbuehl HP. Diastolic dysfunction in aortic stenosis. Circulation 1993;87(suppl IV):IV-73-6.
16. Weber WT, Brilla CG, Campbell SE, et al. Myocardial fibrosis: role of angiotensin II and aldosterone. In: Grobecker H, Heusch G, Stauer BE, eds. Angiotensin and the heart. New York: Springer-Verlag, 1993:107-24.
17. Betocchi S, Cuocolo A, Pace L, et al. Effects of intravenous verapamil administration on left ventricular diastolic function in systemic hypertension. Am J Cardiol 1987;59:624-9.
18. Muiesan ML, Agabiti-Rosei E, Romanelli G, et al. Improved left ventricular systolic and diastolic function after regression of cardiac hypertrophy, treatment withdrawal and redevelopment of hypertension. J Cardiovasc Pharmacol 1991;17(suppl 2):179-81.
19. Applegate RJ, Walsh RA, O'Rourke RA. Frequency-dependent myocardial depression induced by verapamil in conscious dogs. Am J Physiol 1987;253:H487-92.
20. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993;87:86-93.
21. Antony I, Aptecar E, Lerebours G, Nitenberg A. Coronary artery constriction caused by the cold pressor test in human hypertension. Hypertension 1994;24:212-9.
22. Nabel EG, Ganz P, Gordon JB, et al. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 1988;77:43-52.
23. Houghton JL, Smith VE, Strogatz DS, et al. Effect of African-American race and hypertensive left ventricular hypertrophy on coronary vascular reactivity and endothelial function. Hypertension 1997;29:706-14.
24. Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996;94:3115-22.
25. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;94:258-65.
26. Mombouli JV, Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 1995;35: 679-705.
27. Hahn AW, Resink TJ, Scott-Burden T, et al. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regtil 1990;1:649-59.
28. Rubanyi GM, Vanhoutte PM. Oxygen-derived free radicals, endothelium and responsiveness of vascular smooth muscle. Am J Physiol 1986;250:H815-21.
29. Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994;266:H2568-72.
30. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
31. Kiowski W, Luscher TF, Linder L, Buhler FR. Endothelin-1 induced vasoconstriction in man: reversal by calcium channel blockade but not by nitrovasodilators or ERDF. Circulation 1991;83: 469-75.
32. Daugherty A, Rateri DL, Schonfeld SB. Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade. Br J Pharmacol 1987;91:113-8.
33. Stein O, Halperin G, Stein J. Long term effect of verapamil on aortic smooth muscle cells cultured in the presence of hypercholesterolemic serum. Arteriosclerosis 1987;7:585-95.
34. Affolter H, Burkand WP, Pletscher A. Verapamil, an antagonist at 5-hydroxytryptamine receptors of human blood platelets. Eur J Pharmacol 1985;108:157-62.
35. Bache RJ. Effects of calcium entry blockade on myocardial blood flow. Circulation 1989;80(suppl IV):IV-40-6.
36. Kusuoka H, Jacobus WE, Marban E. Calcium oscillations in digitalis-induced ventricular fibrillation: pathogenetic role and metabolic consequences in isolated ferret hearts. Circ Res 1988;62:609-19.
37. Steenbergen C, Hill ML, Jennings RB. Cytoskeletal damage during myocardial ischemia: changes in vinculin immunofluorescence staining during total in vitro ischemia in canine hearts. Circ Res 1987;60:478-86.
38. 2+-dependent protein kinase. Biochem J 1983;209:189-95.
39. Kirchengast M, Hergenroder S, Munter K. Does the combination of an ACE inhibitor and a calcium antagonist enhance cardioprotection? In: Godfraind T, Mancia G, Abbracchio MP, Aguilar-Bryan L, Govoni S, eds. Pharmacological control of calcium and potassium homeostasis. Amsterdam: Kluwer Academic Publishers, 1995:173-9.
40. Olsson G, Rehnqvist N, Sjogren A, et al. Long-term treatment with metoprolol after myocardial infarction: effect on 3-year mortality and morbidity. J Am Coll Cardiol 1985;5:1428-37.
41. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
42. The SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327: 685-91.
43. Pfeffer MA, Braunwald E, Moyè L, et al., for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
44. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
45. Kober L, Torp-Pedersen C, Carlsen J, et al., for the TRACE Study Investigators. A clinical trial of angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after an acute myocardial infarction. N Engl J Med 1995;333: 1670-6.
46. Israeli SPRINT Study Group: Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988;9:354-64.
47. Danish Study Group on Verapamil in Myocardial Infarction. The effect of verapamil on mortality and major events after myocardial infarction: the Danish Verapamil Infarction Trial (DAVIT) II. Am J Cardiol 1990;66:779-85.
48. Hansen J, Hagerup L, Sigurd B, et al. Cardiac events rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol 1997;79: 738-41.